ArticleMediators of inflammation2026
Association Between Atopic Dermatitis and Systemic Immune-Inflammation Index: Evidence From NHANES 1999-2006.
Article in Mediators of inflammation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Systemic Inflammation and Structural Retinal Damage on OCT in Acute Non-Arteritic Central Retinal Artery Occlusion-A Retrospective Study.International journal of molecular sciences · 2026Article
- Association Between Atopic Dermatitis and Systemic Immune-Inflammation Index: Evidence From NHANES 1999-2006.Mediators of inflammation · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Clinical studies have demonstrated that the systemic immune-inflammation index (SII) is widely used to assess immunity and inflammation in patients. However, the association between SII and atopic dermatitis (AD) remains unclear. This study, based on the National Health and Nutrition Examination Survey (NHANES) database, aims to explore the relationship between SII and AD. Methods: This study utilized NHANES data from 1999 to 2006, with a total of 8194 subjects included in the final analysis. We examined the associations between AD, SII, and other covariates by analyzing baseline characteristics and performing correlation analyses. Multivariate generalized linear models (GLMs) were used to analyze the correlation between AD and SII risk. A weighted multivariate logistic regression model was applied to examine the association between SII and AD. Additionally, a nomogram was constructed to predict the risk of developing AD. The eXtreme Gradient Boosting (XGBoost) algorithm was employed to evaluate feature importance. Finally, subgroup analysis was performed to further explore the relationship between SII and AD across different subpopulations. Results: Significant differences were observed between the AD and control groups in terms of race, SII, SII group, and other variables. Furthermore, the Conclusion: Elevated SII is independently associated with increased AD risk. Although the cross-sectional design precludes causal inference, SII represents a cost-effective biomarker for AD risk stratification. Critically, emerging evidence positions SII as a predictor of therapeutic response-particularly to JAK inhibitors and biologics-highlighting its dual utility in risk assessment and precision management of AD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.